ASST Fatebenefratelli Sacco
- Address
- lock Available on a paid plan
Respiratory Tract Diseases
At ASST Fatebenefratelli Sacco in Milan, pediatric research in respiratory tract diseases focuses on children with asthma, severe eosinophilic asthma, and wheezing. These studies are designed to assess new treatment options and better understand how to reduce flare-ups and improve day-to-day breathing control in young patients.
- Evaluating treatments for paediatric asthma and recurrent asthmatic wheeze
- Studying severe eosinophilic asthma to reduce exacerbations and improve symptom control
- Assessing the effectiveness and safety of new approaches for children with uncontrolled breathing problems
The work in this area aims to support safer and more effective care for children living with chronic airway inflammation and repeated asthma attacks.
Virus Diseases
The site also conducts pediatric trials in virus diseases, with a strong focus on COVID-19. Research here is centered on understanding whether new antiviral approaches can help children and adolescents recover more effectively while also confirming how well they are tolerated.
- Investigating COVID-19 treatment options for children and adolescents
- Assessing safety and tolerability of new antiviral therapies in pediatric patients
- Supporting better clinical care for young people affected by viral infection
These studies aim to improve treatment choices for pediatric coronavirus infection and strengthen evidence for use in younger populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Gilead Sciences Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ASST Fatebenefratelli Sacco
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA) | AstraZeneca AB | Phase III | Not Recruiting | Jun 2023 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 1 | Unknown | 2016-05-10 | 2016-05-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.